https://orcid.org/0000-0003-4194-8183
Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Maria Elisa Mancuso, Daniel Eriksson, Aletta Falk, Zalmai Hakimi, Piotr Wojciechowski, Marlena Wdowiak & Robert Klamroth. (2023) Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials. Journal of Blood Medicine 14, pages 427-434.
Read now
Read now
Pooja Gogia, Michael Tarantino, Wolfgang Schramm & Louis Aledort. (2023) New directions to develop therapies for people with hemophilia. Expert Review of Hematology 16:6, pages 417-433.
Read now
Read now
Maria Elisa Mancuso, Giancarlo Castaman, Michal Pochopien, Samuel Aballéa, Aleksandra Drzewiecka, Zalmai Hakimi, Jameel Nazir & Francis Fatoye. (2022) Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe. Journal of Medical Economics 25:1, pages 1068-1075.
Read now
Read now
Katharine Batt, Bob G. Schultz, Jorge Caicedo, Christopher S. Hollenbeak, Neha Agrawal, Sagnik Chatterjee & Michael Bullano. (2022) A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab. Current Medical Research and Opinion 38:10, pages 1685-1693.
Read now
Read now
Johnny Mahlangu. (2022) An update of the current pharmacotherapeutic armamentarium for hemophilia A. Expert Opinion on Pharmacotherapy 23:1, pages 129-138.
Read now
Read now
Articles from other publishers (3)
Nana Kragh, Anna Tytula, Michał Pochopien, Samuel Aballéa, Mondher Toumi, Zalmai Hakimi, Jameel Nazir, Linda Bystrická & Francis Fatoye. (2022)
Cost‐effectiveness of recombinant factor
VIII Fc
versus emicizumab for prophylaxis in adults and adolescents with haemophilia
A
without inhibitors in the
UK
. European Journal of Haematology 110:3, pages 262-270.
Crossref
Crossref
P. A. Zharkov. (2022) Is there any place for replacement therapy of hemophilia A in children in present and future?. Russian Journal of Pediatric Hematology and Oncology 9:3, pages 56-64.
Crossref
Crossref
Angelika Batorova, Ana Boban, Melen Brinza, Toshiko Lissitchkov, Laszlo Nemes, Irena Preložnik Zupan, Petr Smejkal, Nadezhda Zozulya & Jerzy Windyga. (2022) Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A. Journal of Medicine and Life 15:4, pages 570-578.
Crossref
Crossref